Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

Thierry André,Dominique Berton,Giuseppe Curigliano,Susan Ellard,Jose Manuel Trigo Perez,Hendrik-Tobias Arkenau,Cyril Abdeddaim,Victor Moreno,W. Guo,Ellie Im,Naureen Starling

Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

2021

Thierry André
Dominique Berton
Giuseppe Curigliano
Susan Ellard
Jose Manuel Trigo Perez
Hendrik-Tobias Arkenau
Cyril Abdeddaim
Victor Moreno
W. Guo
Ellie Im
Naureen Starling

9Background: Dostarlimab is a humanized anti–PD-1 monoclonal antibody that binds the PD-1 receptor, blocking interaction with ligands PD-L1 and PD-L2. The ongoing phase 1 GARNET study (NCT02715284)...

Keywords:

DNA mismatch repair
Cancer research
anti pd 1
in patient
Receptor
Monoclonal antibody
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations